Australia markets closed

ArriVent BioPharma, Inc. (AVBP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
17.99+0.63 (+3.63%)
At close: 04:00PM EDT
17.99 0.00 (0.00%)
After hours: 04:01PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 581.45M
Enterprise value 431.38M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA -5.78

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-10.05%
S&P500 52-week change 326.43%
52-week high 325.95
52-week low 314.35
50-day moving average 317.88
200-day moving average 318.87

Share statistics

Avg vol (3-month) 3178.93k
Avg vol (10-day) 350.48k
Shares outstanding 533.49M
Implied shares outstanding 633.49M
Float 818.35M
% held by insiders 113.68%
% held by institutions 142.37%
Shares short (15 Apr 2024) 4944.99k
Short ratio (15 Apr 2024) 43.82
Short % of float (15 Apr 2024) 43.91%
Short % of shares outstanding (15 Apr 2024) 42.82%
Shares short (prior month 15 Mar 2024) 495.1k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.72%
Return on equity (ttm)-30.31%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-74.58M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)317.39M
Total cash per share (mrq)9.48
Total debt (mrq)285k
Total debt/equity (mrq)0.09%
Current ratio (mrq)32.82
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-57.59M
Levered free cash flow (ttm)-48.18M